Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 6, 2011, Pages 732-737

  Zhang, Tianyu ^a,b   Li, Si Yang ^a   Williams, Kathy N ^a   Andries, Koen ^c   Nuermberger, Eric L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c TIBOTEC BVBA   (Belgium)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bacillus Calmette Gu rin; Isoniazid; Mouse; Pyrazinamide; Rifampin

Indexed keywords

BCG VACCINE; BEDAQUILINE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; EXPERIMENTAL MODEL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; LATENT TUBERCULOSIS; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; SHORT COURSE THERAPY;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; LATENT TUBERCULOSIS; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; RIFAMPIN; STEM CELLS; TREATMENT OUTCOME;

EID: 80052916123     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201103-0397OC     Document Type: Article

References (28)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response 2010. Geneva: World Health Organization; 2010.WHO/HTM/TB/2010.3.
2. Becerra M, Appleton S, Franke M, Chalco K, Arteaga F, Bayona J, Murray M, Atwood S, Mitnick C. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2010;377:147-152.
3. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
4. Horn DL, Hewlett D Jr, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994;330:1241. (Pubitemid 24122002)
5. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002;167:131-136. (Pubitemid 34791519)
6. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997;24:1264-1265. (Pubitemid 27249040)
7. Lou HX, Shullo MA, McKaveney TP. Limited tolerability of levo- floxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy 2002;22:701-704. (Pubitemid 34596478)
8. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2009;180:1151-1157.
9. Andries K, Verhasselt P, Guillemont J, Gohlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227. (Pubitemid 40116230)
10. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, Gohlmann HWH, Willebrords R, Poncelet A, Guillemont J, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008;283:25273-25280.
11. Rao SPS, Alonso S, Rand L, Dick T, Pethe K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2008;105:11945-11950.
12. Coleman D, Waddell SJ, Mitchison DA. Effects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2011;66:146-150.
13. Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, Cantarero L, Orme IM, Basaraba RJ. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910. Antimicrob Agents Chemother 2007;51:3338-3345. (Pubitemid 350067549)
14. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51:1011-1015. (Pubitemid 46355288)
15. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006;50:3543-3547. (Pubitemid 44684863)
16. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009;180:553-557.
17. Andries K, Gevers T, Lounis N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 2010;54:4540-4544.
18. Diacon A, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-2405.
19. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 2004;72:1065-1071. (Pubitemid 38166689)
20. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005;172:1452-1456. (Pubitemid 43069820)
21. Rosenthal I, Zhang M, Williams K, Peloquin C, Tyagi S, Vernon A, Bishai W, Chaisson R, Grosset J, Nuermberger E. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
22. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-926.
23. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am J Respir Crit Care Med 2005;172:1457-1462. (Pubitemid 43069821)
24. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009;53:4178-4184.
25. Rhoades E, Frank A, Orme I. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis 1997;78:57-66. (Pubitemid 28019788)
26. Hunter RL, Jagannath C, Actor JK. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb) 2007;87:267-278. (Pubitemid 46951032)
27. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffe M, Emile JF, Marchou B, Cardona PJ, et al.. Foamy macrophages from tuberculous patients' granulomas constitute a nutrientrich reservoir for M. tuberculosis persistence. PLoS Pathog 2008;4:e1000204.
28. Sterling TR, Borisov AS, Shang N, Bliven-Sizemore E, Chaisson RE, Gordin F, Hackman J, Hamilton CD, Horsburgh CR, Kerrigan A, et al. Tuberculosis Trials Consortium. The PREVENT TB Study (TB Trials Consortium Study 26) of 3 months of once-weekly rifapentine plus INH vs. 9 months of daily INH for treatment of latent TB infection: first report of results of a multi-center, randomized clinical trial. Presented at the 41st Union Conference on Lung Health, Berlin, November 15, 2010.